1 - Students will be able to demonstrate a comprehensive understanding of business principles as they relate to the biotherapeutics industry
2 - Students will be able to apply their knowledge to overcome problems with commercialisation of research in a biotherapeutics focus area
3 - Students will be able to conduct applied studies on valuation of new drug entities from the biotherapeutics industry
4 - Students will be able to analyse, evaluate and communicate biotechnology research
5 - Students will be able to work alongside scientists and entrepreneurs to develop and commercialise novel biotechnological solutions
6 - Students will be able to develop effective time management, problem-solving and reporting skills as required in a professional workplace
7 - Students will be able to develop a professional approach to engaging with industry and an applied methodology in preparing for employment opportunities
This course is available through the following application route(s)
The MSc in Biotherapeutics & Business educates students on the practical uses of molecular advances in the discovery of proteins and other biomolecular drug candidates and their development into biotherapeutics. It will provide you with a comprehensive understanding of the development of biotherapeutics, beginning with pre-clinical modelling and target identification together with antibody engineering, biochemical and biophysical characterisation, and development issues for bioprocessing. Regulatory issues, and innovation and commercialisation strategies, will also be covered. You will also receive a comprehensive business education. You will learn to identify and solve business problems in local and international settings, enhance your communication and leadership skills, and improve your ability for independent thinking and developing creative solutions.
- The UCD MSc Biotherapeutics and Business programme has a global, multidisciplinary perspective with contributions from national and international academics and experts.
- Students share their firsthand practical experience with other MSc students and professionals from a diverse range of countries and backgrounds and this creates a dynamic learning environment.
About This Course
This graduate degree in Biotherapeutics & Business has been developed in consultation with employers and therefore will be recognised and valued by them. A key feature is the opportunity to carry out a business development plan, which will allow graduates to develop connections with prospective employers, thereby enhancing chances of employment on graduation.
Prospective employers include Abbott, Allergan, Amgen, Baxter Healthcare, Eli Lilly and Co., Dignity Sciences, GSK, Icon Clinical Research, ImmunoGen Inc., Janssen Pharmaceutical Ltd., Johnson & Johnson Ltd., MSD, Quintiles, Quest International, Sandoz and Seroba Life Sciences.
Below is a list of all modules offered for this degree in the current academic year. Click on the module to discover what you will learn in the module, how you will learn and assessment feedback profile amongst other information.
Incoming Stage 1 undergraduates can usually select an Elective in the Spring Trimester. Most continuing undergraduate students can select up to two Elective modules (10 Credits) per stage. There is also the possibility to take up to 10 extra Elective credits.
| Trimester | Credits | |||
|---|---|---|---|---|
Stage 1 Core Modules |
BIOC40180 | Professional Career Development | Autumn | 5 |
Stage 1 Core Modules |
BMOL40120 | The Business of Biotechnology and Science | Autumn | 5 |
Stage 1 Core Modules |
MKT42310 | Marketing Management MSc Bio&B | Autumn | 7.5 |
Stage 1 Core Modules |
PHAR40200 | Biotherapeutic Pipeline I | Autumn | 5 |
Stage 1 Core Modules |
BMGT45430 | Business Strategy | Spring | 7.5 |
Stage 1 Core Modules |
BMOL40380 | Teams in Biotech Enterprise | Spring | 5 |
Stage 1 Core Modules |
FIN41440 | Corporate Finance (BB) | Spring | 7.5 |
Stage 1 Core Modules |
PHAR40210 | Biotherapeutic Pipeline II | Spring | 5 |
Stage 1 Core Modules |
PHAR40220 | Systems Biology in Drug Dev | Spring | 5 |
Stage 1 Core Modules |
BMOL40130 | Feasibility and Business Plan | Summer | 20 |
Stage 1 Core Modules |
PHAR40350 | Biotherapeutics Case Study | Summer | 10 |
Stage 1 Options - A) Min 1 of: (Options) Select from the following |
BIOC40250 | Biomedical Diagnostics&Devices | Autumn | 7.5 |
Stage 1 Options - A) Min 1 of: (Options) Select from the following |
MICR40010 | Recombinant DNA Technology | Autumn | 5 |
Stage 1 Options - A) Min 1 of: (Options) Select from the following |
BMOL40190 | Multicellular Systems | Spring | 5 |
Stage 1 Options - A) Min 1 of: (Options) Select from the following |
CELB40160 | HCS Microscopy | Spring | 5 |
Stage 1 Options - A) Min 1 of: (Options) Select from the following |
MICR40100 | Emerging Issues in Biotechnology | Spring | 5 |
Stage 1 Options - A) Min 1 of: (Options) Select from the following |
PHAR40240 | Regulatory Affairs for Life Sciences | Spring | 5 |
Associate Professor David O’Connell
Lecturer in Biochemistry & Pharmacology
My core research focus is on the activity of calcium-binding proteins involved in homeostatic mechanisms in the cell using an integrated platform of proteomic technologies. I have patented a novel affinity tag platform for improved protein immobilisation for purification, biophysical analysis and detection in multiple biopharmaceutical applications.
EU fee per year - € 16400
nonEU fee per year - € 29100
***Fees are subject to change
Tuition fee information is available on the UCD Fees website. Please note that UCD offers a number of graduate scholarships for full-time, self-funding international students, holding an offer of a place on a UCD graduate degree programme. For further information please visit International Scholarships.
Candidates must have obtained at least an upper Second Class Honours (2:1) Grade or equivalent in an honours BSc in Biotechnology, Biochemistry, Microbiology, Genetics, Neuroscience, Physiology, Pharmacology, Medicinal Chemistry or an equivalent qualification.
If English is not your native language, unless you have done your primary degree through English in an English speaking country, an English language qualification is required for all programmes. English Language qualifications include a minimum score of 550 (213 computer based) for Test of English as a Foreign Language (TOEFL), or 6.5 (with a score of 6 obtained in each category) for International English Language Testing System (IELTS). Other evidence of proficiency in English may be accepted such as the Cambridge Certificate. Tests used as evidence of language proficiency must have been completed within the last 12 months.
2 academic references will be required, at least one to be from a science faculty member.
Students meeting the programme’s academic entry requirements but not the English language requirements, may enter the programme upon successful completion of UCD’s Pre-Sessional or International Pre-Master’s Pathway programmes. Please see the following link for further information http://www.ucd.ie/alc/programmes/pathways/
These are the minimum entry requirements – additional criteria may be requested for some programmes
Full Time option suitable for:
Domestic(EEA) applicants: Yes
International (Non EU) applicants: Yes
How to Apply
General application route(s) for Irish/UK/EU applicants* for International (non-EU) applicants* to Biotherapeutics & Business:
| ROWCLASS | Apply to | Application Type | ||
|---|---|---|---|---|
| showAudience-audienceEU showAudience-audienceInt | F103 Biotherapeutics & Business Master of Science |
Full-Time Commencing September 2024 |
Graduate Taught | Closed |
| showAudience-audienceEU showAudience-audienceInt | F103 Biotherapeutics & Business Master of Science |
Full-Time Commencing September 2025 |
Graduate Taught | Apply |